The global monoclonal antibody therapeutic market size expected to be valued at USD 9,198.4 million and growing at a CAGR of 6.9% during the forecast period 2021-2026. There are around 70 monoclonal antibody products in the market by 2020 and the sales are estimated to be million which is consider as the key driver. Restrain which hung the global monoclonal antibody therapeutic are many drugs like Abagovomab, Actoxumab in phase II and still waiting for approval which can be consider as a key challenge. The biggest opportunity is opened up due to various chronic disorder hence huge growth in the global monoclonal antibody therapeutic market is been expected. Monoclonal antibodies are a type of immunotherapy that is created in a lab and consists of several copies of a single antibody. The US Food and Drug Administration has approved several monoclonal antibodies to treat inflammatory, cancer, and other disorders (FDA). Monoclonal antibodies are classified as murine, chimeric, humanised, or human, depending on the source. Murine antibodies are produced solely from a murine source, whereas chimeric antibodies have variable murine origins and constant human origins. This report studies global monoclonal antibody therapeutic market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities).